

Mauro Bologna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5414000/publications.pdf>

Version: 2024-02-01

68
papers

2,691
citations

172207

29
h-index

197535

49
g-index

69
all docs

69
docs citations

69
times ranked

3339
citing authors

#	ARTICLE	IF	CITATIONS
1	Psychoneuroendocrinology-based meditation (PNEIMED) training reduces salivary cortisol under basal and stressful conditions in healthy university students: Results of a randomized controlled study. <i>Explore: the Journal of Science and Healing</i> , 2020, 16, 189-198.	0.4	17
2	Immunobiologia vaccinale: antigeni, anticorpi e memoria immunitaria. <i>Pnei Review</i> , 2018, , 7-17.	0.1	0
3	Leptin contributes to long-term stabilization of HIF-1 α in cancer cells subjected to oxygen limiting conditions. <i>Cancer Letters</i> , 2016, 376, 1-9.	3.2	20
4	Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. <i>BMC Cancer</i> , 2014, 14, 154.	1.1	92
5	Biological Agents and Bioterrorism. <i>NATO Science for Peace and Security Series A: Chemistry and Biology</i> , 2014, , 1-10.	0.5	2
6	Immunological Defence Mechanisms Against Biological Agents. <i>NATO Science for Peace and Security Series A: Chemistry and Biology</i> , 2014, , 11-16.	0.5	1
7	Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2387-2398.	3.1	24
8	Biomarkers in Prostate Cancer. , 2012, , 355-380.		4
9	Tissue print of prostate biopsy: a novel tool in the diagnostic procedure of prostate cancer. <i>Diagnostic Pathology</i> , 2011, 6, 34.	0.9	10
10	Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5928-5933.	1.0	48
11	EphA2 Induces Metastatic Growth Regulating Amoeboid Motility and Clonogenic Potential in Prostate Carcinoma Cells. <i>Molecular Cancer Research</i> , 2011, 9, 149-160.	1.5	63
12	New pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. <i>FASEB Journal</i> , 2010, 24, 2881-2892.	0.2	26
13	Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2010, 119, 557-563.	0.6	21
14	Receptor Activator of NF- κ B Ligand Enhances Breast Cancer-Induced Osteolytic Lesions through Upregulation of Extracellular Matrix Metalloproteinase Inducer/CD147. <i>Cancer Research</i> , 2010, 70, 6150-6160.	0.4	54
15	Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. <i>Endocrine-Related Cancer</i> , 2009, 16, 401-413.	1.6	63
16	Her2 crosstalks with TrkA in a subset of prostate cancer cells: Rationale for a guided dual treatment. <i>Prostate</i> , 2009, 69, 337-345.	1.2	9
17	Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1512-1516.	1.0	27
18	Bicalutamide Demonstrates Biologic Effectiveness in Prostate Cancer Cell Lines and Tumor Primary Cultures Irrespective of Her2/neu Expression Levels. <i>Urology</i> , 2009, 74, 452-457.	0.5	5

#	ARTICLE	IF	CITATIONS
19	Kinase-Dependent and -Independent Roles of EphA2 in the Regulation of Prostate Cancer Invasion and Metastasis. <i>American Journal of Pathology</i> , 2009, 174, 1492-1503.	1.9	96
20	Neuroendocrine transdifferentiation induced by VPA is mediated by PPAR γ 3 activation and confers resistance to antiproliferative therapy in prostate carcinoma. <i>Prostate</i> , 2008, 68, 588-598.	1.2	10
21	Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. <i>Prostate</i> , 2008, 68, 793-801.	1.2	31
22	Akt downmodulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. <i>Prostate</i> , 2008, 68, 965-974.	1.2	29
23	Effects of Dutasteride on Prostate Carcinoma Primary Cultures: A Comparative Study With Finasteride and MK386. <i>Journal of Urology</i> , 2008, 180, 367-372.	0.2	18
24	Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. <i>FASEB Journal</i> , 2008, 22, 1560-1571.	0.2	60
25	Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells. <i>Endocrine-Related Cancer</i> , 2008, 15, 91-100.	1.6	24
26	Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. <i>Endocrine-Related Cancer</i> , 2007, 14, 601-611.	1.6	29
27	Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. <i>Oncology Reports</i> , 2007, 18, 503.	1.2	1
28	Surgical and Biologic Outcomes After Neoadjuvant Bicalutamide Treatment in Prostate Cancer. <i>Urology</i> , 2007, 70, 728-733.	0.5	35
29	Identification of a Novel Pyrazolo[3,4-d]pyrimidine Able To Inhibit Cell Proliferation of a Human Osteogenic Sarcoma in Vitro and in a Xenograft Model in Mice. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5579-5588.	2.9	79
30	In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. <i>Prostate</i> , 2007, 67, 1255-1264.	1.2	20
31	Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. <i>Oncology Reports</i> , 2007, 18, 503-11.	1.2	11
32	Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. <i>European Journal of Cancer</i> , 2006, 42, 2838-2845.	1.3	62
33	Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. <i>Anti-Cancer Drugs</i> , 2006, 17, 1141-1150.	0.7	33
34	Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 161-172.	1.3	126
35	Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. <i>Endocrine-Related Cancer</i> , 2006, 13, 197-210.	1.6	79
36	Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 243-254.	1.2	8

#	ARTICLE	IF	CITATIONS
37	Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. <i>Thrombosis and Haemostasis</i> , 2005, 93, 964-975.	1.8	93
38	Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. <i>International Journal of Oncology</i> , 2005, 26, 1353.	1.4	3
39	Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. <i>International Journal of Oncology</i> , 2005, 26, 1353-62.	1.4	2
40	Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 217-221.	1.2	24
41	Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. <i>Prostate</i> , 2004, 59, 157-166.	1.2	56
42	Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice. <i>International Journal of Cancer</i> , 2004, 110, 125-133.	2.3	42
43	An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. <i>International Journal of Cancer</i> , 2004, 112, 909-919.	2.3	108
44	Evaluation of metastatic potential in prostate carcinoma: an in vivo model. <i>International Journal of Oncology</i> , 2004, 25, 1713-20.	1.4	12
45	Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003, 129, 165-174.	1.2	71
46	Characterization of Prostate Cancer DU145 Cells Expressing the Recombinant Androgen Receptor. <i>Oncology Research</i> , 2003, 14, 101-112.	0.6	24
47	Osteopontin Modulates Prostate Carcinoma Invasive Capacity through RGD-Dependent Upregulation of Plasminogen Activators. <i>Biological Chemistry</i> , 2002, 383, 229-234.	1.2	33
48	Bombesin-Dependent Pro-MMP-9 Activation in Prostatic Cancer Cells Requires $\alpha 2$ 1 Integrin Engagement. <i>Experimental Cell Research</i> , 2002, 280, 1-11.	1.2	22
49	Type 5 phosphodiesterase expression in the human vagina. <i>Urology</i> , 2002, 60, 191-195.	0.5	136
50	Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures. <i>Anticancer Research</i> , 2002, 22, 2917-22.	0.5	7
51	Agar specimen orientation technique revisited: A simple and effective method in histopathology. <i>Annals of Diagnostic Pathology</i> , 2001, 5, 107-109.	0.6	12
52	Osteoblast-derived TGF- β 1 modulates matrix degrading protease expression and activity in prostate cancer cells. <i>International Journal of Cancer</i> , 2000, 85, 407-415.	2.3	59
53	Osteoblast-derived TGF- β 1 modulates matrix degrading protease expression and activity in prostate cancer cells. , 2000, 86, 888-888.		16
54	Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 163-170.	1.7	74

#	ARTICLE	IF	CITATIONS
55	Osteoblast conditioned media contain TGF- β 1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. , 1999, 81, 395-403.		78
56	Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clinical and Experimental Metastasis, 1998, 16, 513-528.	1.7	82
57	In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. , 1998, 75, 418-431.		54
58	Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. International Journal of Cancer, 1996, 69, 386-393.	2.3	50
59	Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. , 1996, 69, 386.		4
60	Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology, 1995, 45, 282-290.	0.5	61
61	Early Diagnosis of Prostatic Carcinoma May Be Achieved through in vitro Culture of Tumor Cells Harvested by Prostatic Massage. European Urology, 1993, 24, 148-155.	0.9	10
62	Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer, 1990, 63, 1714-1720.	2.0	199
63	Short-Term Tissue Culture of Prostatic Carcinoma Samples Provides Useful Biological Parameters Related to Patient Prognosis. European Urology, 1988, 15, 243-247.	0.9	9
64	Early Diagnosis of Prostatic Carcinoma Based on in vitro Culture of Viable Tumor Cells Harvested by Prostatic Massage. European Urology, 1988, 14, 474-476.	0.9	15
65	A method for double immunofluorescent staining by the indirect procedure with antibodies of the same isotype. Journal of Immunological Methods, 1986, 86, 151-153.	0.6	7
66	High-performance liquid chromatographic procedure for the quantitation of norfloxacin in urine, serum and tissues. Biomedical Applications, 1984, 309, 177-182.	1.7	28
67	BACTERICIDAL INTRAPROSTATIC CONCENTRATIONS OF NORFLOXACIN. Lancet, The, 1983, 322, 280.	6.3	19
68	Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients. Oncology Reports, 0, , .	1.2	5